Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( P1101combined with standard of care (SOC) compared with standard care alone in hospitalized adults with moderate COVID 19.
Epistemonikos ID: 210a7badfd43f26c93882a52fb694eb2a1cc23ed
First added on: Mar 16, 2023